KanonCure

Message from CEO

  Many patients suffer for liver diseases all over the world, but the patients who can receive the donor liver are very little. For the liver disease treatment, the liver cell sheets, which made of mesenchymal stem cells (MSCs) in human's living body, have been developed by Prof. Goshi Shiota of Tottori University. (Sci Rep. 2015, 5: 16169.)
  Our cell sheets treatment can just put cell sheets onto liver surface, and makes both acute injuring and liver fibrosis caused by chronic injuring decrease. Liver fibrosis become worse to liver cirrhosis and carcinogenesis. So, we expect that liver cell sheets will be an effective treatment for these liver diseases.
  We are challenging research and development in order to offer you these wonderful technology. We will start clinical trial in 2020, and get “conditional approval in Japan” for clinical use. Moreover, we arrange the inside system for IPO, to sap 2nd and 3rd research pipelines.

September 2018
Takeharu HORIKAWA
President and CEO, KanonCure Inc.

About Us

Name KanonCure Inc.
Head Office Tottori Univ. Alesco Bldg. 604,
86 Nishi-cho, Yonago, Tottori,
683-0826 Japan
TEL:+81-50-6863-4511
Established April 25, 2016
Capitalization JPY 53,000,000 Yen
President & CEO Takeharu HORIKAWA
Business Overview  We are focused on regenerative medical products.
 We develop, produce and sell the medical products for treatment, prevention and check of disease as well as regenerative medicine.
 We're also doing guidance and advice of regenerative medical area, and are also accepting co-development and research outsourcing from you.

<< Back